No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
MRUS Merus
- 56.550
- -1.100-1.91%
Close Jun 14 16:00 ET
3.75BMarket Cap-20714P/E (TTM)
58.150High55.280Low566.65KVolume57.240Open57.650Pre Close31.90MTurnover1.06%Turnover RatioLossP/E (Static)66.24MShares61.61052wk High10.72P/B3.02BFloat Cap19.80552wk Low--Dividend TTM53.37MShs Float61.610Historical High--Div YieldTTM4.98%Amplitude7.255Historical Low56.289Avg Price1Lot Size
Pre-Market
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Merus Is Maintained at Buy by Stifel
Merus Is Maintained at Buy by Stifel
Express News | Merus NV : Stifel Raises Target Price to $99 From $90
Merus(MRUS.US) Officer Sells US$475.46K in Common Stock
$Merus(MRUS.US)$ Officer Shuman Harry sold 8,300 shares of common stock on Jun 10, 12, 2024 at an average price of $57.284 for a total value of $475.46K.Source: Announcement What is statement of chang
Merus Insider Sold Shares Worth $475,456, According to a Recent SEC Filing
Harry Shuman, Vice President, Controller, Principal Accounting Officer, on June 10, 2024, sold 8,300 shares in Merus (MRUS) for $475,456. Following the Form 4 filing with the SEC, Shuman has control o
Merus(MRUS.US) Officer Sells US$317.35K in Common Stock
$Merus(MRUS.US)$ Officer Shuman Harry sold 6,000 shares of common stock on Jun 4, 2024 at an average price of $52.892 for a total value of $317.35K.Source: Announcement What is statement of changes in
BofA Securities Maintains Merus(MRUS.US) With Buy Rating, Maintains Target Price $76
BofA Securities analyst Tazeen Ahmad maintains $Merus(MRUS.US)$ with a buy rating, and maintains the target price at $76.According to TipRanks data, the analyst has a success rate of 48.3% and a total
Comments
$SPDR S&P Biotech ETF(XBI.US$
$Merck & Co(MRK.US$ x $Immunovant(IMVT.US$
$Eli Lilly and Co(LLY.US$ x $Cytokinetics(CYTK.US$ (and soon)
$Regeneron Pharmaceuticals(REGN.US$ x $Apellis Pharmaceuticals(APLS.US$ (panache & brash)
$Gilead Sciences(GILD.US$ x % $Madrigal Pharmaceuticals(MDGL.US$ (liver king)
$Bristol-Myers Squibb(BMY.US$ x $Iovance Biotherapeutics(IOVA.US$ (cell Tx boost needed)
$Eli Lilly and Co(LLY.US$ x $Merus(MRUS.US$ (partner n...
$Merck & Co(MRK.US$ x $Immunovant(IMVT.US$
$Eli Lilly and Co(LLY.US$ x $Cytokinetics(CYTK.US$ (and soon)
$Regeneron Pharmaceuticals(REGN.US$ x $Apellis Pharmaceuticals(APLS.US$ (panache & brash)
$Gilead Sciences(GILD.US$ x % $Madrigal Pharmaceuticals(MDGL.US$ (liver king)
$Bristol-Myers Squibb(BMY.US$ x $Iovance Biotherapeutics(IOVA.US$ (cell Tx boost needed)
$Eli Lilly and Co(LLY.US$ x $Merus(MRUS.US$ (partner n...
3
Merus' high P/S ratio is worrisome due to underwhelming revenue forecasts. The company's declining revenue growth and below-industry growth predictions may cause a drop in the P/S ratio, risking shareholders' investments.
1
Following a turbulent period, there has been a notable change in the trajectory of biotech stocks. After experiencing significant downturns in 2021 and 2022, the $SPDR S&P Biotech ETF(XBI.US$ has seen an increase of 5.5% in the current year. However, it continues to trail considerably behind the $S&P 500 Index(.SPX.US$, which has achieved a 24% gain. However, analysts indicate that the previously cool sent...
28
1
$Merus(MRUS.US$ 71.55% is institutions owned, don't sell for cheap, at least 30.
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg